Msd R&d (china) Co., Ltd.
Clinical trials sponsored by Msd R&d (china) Co., Ltd., explained in plain language.
Research and development subsidiary of Merck & Co., a global pharmaceutical company.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for Tough-to-Treat blood cancer: MK-1045 enters human trials
Disease control Recruiting nowThis study tests a new drug called MK-1045 (CN201) in people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking how well the drug works. Ab…
Phase: PHASE1, PHASE2 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called MK-1045 (CN201) in about 100 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. MK-1045 is an immunotherapy designed to help the immune system fight the cancer. The main goals are to check …
Phase: PHASE1 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC